Mitochondrial activation in transplanted cells promotes regenerative therapy for heart healing
A Hokkaido University study finds regenerative therapy to treat heart failure is more effective when the mitochondria of the regenerative cells are activated prior to treatment.
A research team led by Professor Yuma Yamada of Hokkaido University's Faculty of Pharmaceutical Science has developed a technique to promote cardiac regeneration by delivering mitochondrial activators to cardiac progenitor cells. Their findings were published in the Journal of Controlled Release.
"Cardiomyocytes efficiently use the mitochondrial tricarboxylic acid cycle to produce large amounts of adenosine triphosphate from several substrates via oxidative phosphorylation (OXPHOS)," explains Yamada. "Based on the energy metabolism of cardiomyocytes, we hypothesized that activating the mitochondrial function of transplanted cells may improve the outcome of cell transplantation therapy."
Yamada and his group have previously developed a drug delivery system called MITO-Porter, which targets mitochondria within cells. In the current study, they used MITO-Porter to deliver Coenzyme Q10 (CoQ10) to human cardiosphere-derived cells (CDCs), activating their mitochondria (human MITO cells). When these human MITO cells were transplanted into a rat model of myocardial ischemia-reperfusion injury, cardiac function significantly improved. A remarkable ability to suppress myocardial fibrosis was also demonstrated, which could prevent incorrect healing of heart tissue.
Human MITO cells exhibited the ability to improve cardiac function not only through myocardial administration but also with intravenous administration, hinting at versatile therapy applications. The study also suggests that human MITO cells may possess a higher survival rate even in environments characterized by increased Reactive Oxygen Species (ROS), which occurs due to mitochondrial damage.
The researchers employed metabolomics analysis to quantitatively assess metabolic changes in the chronic phase of heart failure in rat models. The study proposes that after myocardial administration of human MITO cells, amino acid synthesis in myocardial TCA cycle in chronic heart failure was enhanced. This suggests that the administration of human MITO cells to the myocardium during the acute phase of myocardial injury may allow the myocardium to effectively utilize the TCA cycle during the chronic phase.
"The strides made in mitochondrial activation bring us closer to a future where cardiac therapy is not just a treatment but a transformative intervention. As we unlock the secrets within our cells, a healthier and more resilient heart stands on the horizon, promising a new dawn in the fight against heart failure," Yamada concludes.
Contacts:
Professor Yuma Yamada
Faculty of Pharmaceutical Sciences
Hokkaido University
Tel: +81-11-706-3735
Email: [email protected]
Public Relations & Communications Division
Office of Public Relations and Social Collaboration
Hokkaido University
Tel: +81-11-706-2186
Email: [email protected]
Paper:
DOI: 10.1016/j.jconrel.2024.01.058
Funding:
This work was supported, in part, by the Ministry of Education, Culture, Sports, Science and Technology of
Photo: https://mma.prnewswire.com/media/2347193/Hokkaido_Research_Team.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/mitochondrial-activation-in-transplanted-cells-promotes-regenerative-therapy-for-heart-healing-302070984.html
SOURCE Hokkaido University
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AEON Launches Agentic Checkout, Powered by AI Card for Autonomous Commerce
- Western Computer Achieves the 2026/2027 Microsoft AI Business Solutions Inner Circle Award
- Urban Infrastructure Group Inc. Announces Exercise of Warrants and Filing of Early Warning Report by Director
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share